** Shares of Caribou Biosciences CRBU.O rise 3% to 89 cents in extended trading
** Co says it is reducing workforce by 32% to extend its cash runway into H2 of 2027; as of March 31, co had about $212.5 mln in cash
** CRBU had 147 full-time employees as of March 1 - SEC filing
** Co says it will prioritize two cancer therapy programs, CB-010 and CB-011
** Also says it is stopping work on lupus and leukemia treatment trials
** As of last close, stock down 45% YTD
(Reporting by Kamal Choudhury in Bengaluru)
((Kamal.Choudhury@thomsonreuters.com;))
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。